Correction of the press release published November 24, 2020: It has come to our attention that a mistake was printed in the percentage of control patients in the EAP who survived to day 28. The correct percentage is 27%, not 17% of the control patients, all treated with best available intensive care unit (ICU) Standard of Care, survived to day 28. This has been corrected in the text below.

GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / November 25, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company") and NeuroRx, Inc., announced that more than 175 patients with Critical COVID-19 and Respiratory Failure who also have a severe comorbidity have now been entered into an Expanded Access Protocol (EAP) with RLF-100(TM) in the United States.

All patients had severe comorbidities (such as organ transplant, recent heart attack, and cancer) that rendered them ineligible for the ongoing randomized, controlled phase 2b/3 trial being conducted to ascertain safety and efficacy of RLF-100(TM), and all patients were deteriorating despite treatment with approved therapies for COVID-19 (see www.clinicaltrials.gov NCT 04311697). Of the 90 patients who have so far reached 28 days of follow-up, 72% survived to day 28.

As previously reported by Youssef and coworkers (http://dx.doi.org/10.2139/ssrn.3665228), at Houston Methodist Hospital, 21 patients treated with RLF-100(TM) under the EAP were compared to 24 control patients treated in the same setting. Only 27% of the control patients, all treated with best available intensive care unit (ICU) Standard of Care, survived to day 28. The survival rate with RLF-100(TM) reported today is comparable to that seen among the open-label patients treated with RLF-100(TM) by Youssef et al. Despite advancements in treating COVID-19, survival for the patients at highest risk due to severe comorbidities has remained dismal in the absence of an effective therapy.

Notably, in the EAP, no drug-related Serious Adverse Events have been reported to date among these patients nor the 160 patients randomized to RLF-100(TM) vs. placebo in the U.S. phase 2b/3 clinical trial currently underway. Thus, from a risk/benefit perspective, while the benefit of RLF-100(TM) has not yet been proven in a randomized prospective trial, no serious risk has been identified so far.

Currently, 25 U.S. hospitals have enrolled patients in the EAP, nearly all of which are community hospitals, suggesting that RLF-100(TM) can demonstrate effectiveness in the hands of front-line physicians who deliver the majority of care to patients with Critical COVID-19. Physicians enrolling patients in the EAP have routinely reported that initial patients at their sites have frequently been in the ICU for several weeks without recovery prior to treatment with RLF-100(TM). As patients are treated earlier in the course of their ICU stay, there is an emerging clinical impression that RLF-100(TM) has an even greater impact on recovery.

"We are reassured that emerging real-world data on the use of RLF-100(TM) in improving survival in patients with Critical COVID-19 are comparable to results seen in the hands of major academic teaching centers. We hope that these findings are viewed as encouraging at a time when many Americans, including the doctors, nurses, and other front-line caregivers who are the heart of our initiative, are celebrating the Thanksgiving holiday at a distance from their loved ones. We look forward to completing enrollment and reporting the results of our pivotal U.S. clinical trial," said Prof. Jonathan C. Javitt, MD, MPH, CEO and founder of NeuroRx, Inc.

###

ABOUT VIP IN LUNG INJURY
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type 2 cell, that is critical to transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.

COVID-19-related death is primarily caused by respiratory failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.

Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and are essential for oxygen exchange. Other than RLF-100(TM), no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.

ABOUT RLF-100(TM)
RLF-100(TM) (Aviptadil) is a formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Sami Said's original work at Stony Brook University, for which Stony Brook was awarded an FDA Orphan Drug Designation in 2001. VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100(TM) for the treatment of COVID-19 and awarded Fast Track designation. RLF-100(TM) is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 150 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100(TM) under FDA-approved protocols. Information on the RLF-100(TM) Expanded Access program is at https://www.neurorxpharma.com/our-services/rlf-100.

ABOUT RELIEF THERAPEUTICS HOLDING AG
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the U.S. and multiple other countries covering potential formulations of RLF-100(TM).

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on the OTCQB under the symbol RLFTF.

ABOUT NEURORX INC.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100(TM), NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. The results reported herein may or may not be indicative of the results of future and larger clinical trials for RLF-100(TM) for the treatment of COVID-19. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

CORPORATE CONTACT
RELIEF THERAPEUTICS Holding AG
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
Mail: contact@relieftherapeutics.com
www.relieftherapeutics.com

NeuroRx, Inc.
Jonathan C. Javitt, M.D., MPH
Chairman and Chief Executive Officer
Mail: ceo@neurorxpharma.com

MEDIA CONTACT:
Relief (Europe)
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

NeuroRx (United States)
David Schull
Russo Partners, LLC
Tel.: +1 (0) 858-717-2310
Mail: david.schull@russopartnersllc.com

INVESTOR RELATIONS
Relief (Europe)
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

NeuroRx (United States)
Brian Korb
Solebury Trout
Tel.: +1 (0) 917-653-5122
Mail: bkorb@troutgroup.com

SOURCE: Relief Therapeutics Holdings AG

ReleaseID: 618414

NEWARK, NJ / ACCESSWIRE / November 25, 2020 / Safety First Healthcare Corp, a Delaware company registered with the Securities & Exchange Commission as a US-form 10 public company with factories in Vietnam specializing in the personal protective equipment business, is seeing another significant surge in demand for PPE products. This new wave is due to the large number of rising cases of Covid-19 and stock piling of PPE equipment globally. The products most in demand are N95 masks and nitrile gloves. However, with the current global surge in Covid-19 cases, Safety First Healthcare is seeing substantial rise in demand for 4-ply surgical masks.

Shaun Morgan, CEO of Safety First Healthcare said, "We are seeing increased purchasing from rising Covid-19 cases and medical community stock piling for the coming winter months. There is also the anticipated mask mandates many governments around the world are implementing or expected to implement."

Safety First Healthcare has two types of 4-ply surgical masks; Protection Masks and Advanced Protection Masks. The difference between the two types is that Protection Masks have a higher than 90% effective filtration layer and the Advanced Protection Masks have a higher than 95% effective filtration layer. Safety First Healthcare Nut95 masks are 5-layer masks which have two higher than 95% effective filtration layers. The filtration layer of all masks is made of a non-woven melt-blown, anti-bacterial fabric.

"The filtration layer of a mask is the most expensive part of mask production. This one layer is 10 times the cost of the other layers of the mask. Therefore, the overall cost of the mask is dependent on the level of protection the filtration layer provides," noted Fredy Bush, Advisory Chairwoman. "With the general public now wearing masks, we are seeing orders for surgical 4-ply masks and N95 masks, which offer high levels of protection, being ordered outside the medical profession. Various types of commercial enterprises such as restaurants and courier companies are now ordering this level of masks for their employees."

Safety First Healthcare is able to produce 250 million 4-ply surgical masks per week and currently has 100 million Advanced Protection Masks in inventory in response to the large number of orders. Additionally, Safety First Healthcare has 5 million Nut95 (N95) masks in inventory.

"Many countries don't have mask manufacturing locally therefore we feel it is incumbent upon companies like Safety First Healthcare to produce large quantities of masks to help governments and people globally," noted Shaun Morgan.

Safety First masks have FDA certification for medical masks and respirator mask, Health Canada, Certificate of Conformity (CE), International Organization for Standardization (ISO), Vinacontrol and other certifications. Many of the certifying bodies conduct a number of tests on each type of mask to qualify for certification. Organizations like ISO check for international standards and best practices of processes and procedures in manufacturing.

Safety First Healthcare provides SGS inspections if requested by the client. An SGS inspection checks for quality and quantity prior to the client taking possession of the goods.

Safety First Healthcare – Premier Producer of Personal Protection Equipment (PPE): http://SafetyFirstHealthcareNews.com

Safety First Healthcare CEO Shaun G. Morgan On the Extensive Offering of FDA-Certified Medical Products: https://www.biospace.com/article/releases/safety-first-healthcare-ceo-shaun-g-morgan-on-the-extensive-offering-of-fda-certified-medical-products/

Safety First Healthcare CEO Shaun G. Morgan On Mobilizing Resources to Help Address PPE Shortage: https://www.yahoo.com/news/safety-first-healthcare-ceo-shaun-163500578.html

Contact Information:
Safety First Healthcare
Fredy Bush
26th Floor, One Gateway Center
Newark, NJ 07102
1-800-657-5645
info@safetyfirst.healthcare
https://safetyfirst.healthcare

SOURCE: Safety First Healthcare

ReleaseID: 618398

What to expect when your newborn needs special care

MISSION, KS / ACCESSWIRE / November 25, 2020 / (Family Features) If you have a baby who is born too early or has serious health problems, he or she may be admitted to the neonatal intensive care unit (NICU), a hospital unit that provides around-the-clock specialized care to newborns.

The NICU can be an overwhelming place with lots of machines, hospital staff and medical terms. If you or someone close to you is pregnant, understanding what to expect if a NICU stay is required can help you focus less on the surroundings and uncertainty and more on taking care of the new baby and yourself.

Learn the ins and outs of the NICU with information from March of Dimes, the nation's leading nonprofit that advocates for the health of all moms and babies, which partners with hospitals across the country through its NICU Family Support® program to provide in-person and online support for families with babies in the NICU.

Common NICU Conditions

Babies born too early and other sick newborns may face a variety of medical issues. Among common causes for a NICU stay may include preterm birth, complications during labor and delivery, birth defects, genetic conditions or other illnesses.

Tests to Expect in the NICU

Your baby may have tests and monitoring done in the NICU to determine health conditions and treatments for him or her to grow and be healthy. Some tests, like blood tests, are common. Others are just for babies with certain health conditions. Depending on his or her condition, your baby might need scans or imaging to find out what's happening, like a CT scan, echocardiogram, MRI, ultrasound or X-ray. You can also expect various screenings for vision and hearing, and monitoring for things like weight changes and urine tests, which can tell health care providers about your baby's overall condition.

Coping with Stress in the NICU

When your baby is in the NICU, it may be hard to think about taking care of yourself. However, taking care of yourself can help you stay well and have more energy to spend time with your baby.

Stick to a daily routine. Every day, take a shower, eat regular meals, drink plenty of water and get a good night's sleep. As part of your routine, decide when you want to be with your baby in the NICU. Schedule breaks from the NICU. It's OK to make time for yourself and the rest of your family.
Follow COVID-19 protocols while connecting with other NICU families at NICU classes, in the family lounge or in the NICU hallways. They may understand what you're experiencing and be able to offer guidance. You can find a supportive online environment that provides advice and resources, and allows you to connect with communities of other NICU families that have had similar experiences, at marchofdimes.org/online-communities.aspx.
You may experience many emotions when your baby's in the NICU. Talking to a counselor may help you sort through your feelings. This may be someone from the NICU staff, a social worker or your religious or spiritual leader. Sometimes it's helpful to talk to someone trained to help you work through stress and navigate challenges like going back to work, the baby blues or postpartum depression.

Paying for Your Baby's NICU Stay

Health insurance helps pay for medical care. You may get health insurance from your employer, from the government or buy it on your own. If your insurance doesn't cover all the health care costs for your baby, ask the NICU social worker or case manager about your options. A social worker can assist you with finding resources and services to help care for your baby. You can also meet with the hospital's finance department about setting up a payment plan. A case manager may also oversee a baby's discharge from the hospital and help set up home care services and supplies, if needed.

Learn more about the NICU and find articles and resources for your family at marchofdimes.org/NICU.

Answers at Your Fingertips

Having a newborn in the NICU can be overwhelming. You're likely to have lots of questions and need access to tools that help you through the NICU stay. You can learn about NICU staff, policies, equipment and terminology on your own schedule with the March of Dimes My NICU Baby App, which provide answers, tools and support so you can focus on your baby during what is often a difficult time.

The app (available for iOS and Android devices) was developed to help parents cope with a baby's early birth, complications like birth defects and other issues that may lead to a NICU stay. It includes features like tracking breastfeeding sessions, breast pumping and kangaroo care time, taking photos and connecting with other families with similar experiences.

Life After the NICU

It can be hard to get used to being at home with your baby after a stay in the NICU. These tips can help you adjust to life at home with your baby:

When you have questions about your baby or your baby's care, call your child's pediatrician.
Take your baby to all his or her well-child visits. These are medical checkups where your baby's health care provider checks his or her health and development to make sure things are going well.
Ask family members, friends and neighbors for help at home. Tell them exactly what you need them to do. For example, tell them if you need help with the laundry, running errands or taking care of your other children.
Take extra steps to keep your baby healthy while he or she is building an immune system, especially during cold and flu season. Limit the number of visitors and only welcome those who are healthy. Ask visitors to wash their hands before touching the baby. Do not allow smoking near your child.

Photos courtesy of Getty Images

Michael French
mfrench@familyfeatures.com
1-888-824-3337
editors.familyfeatures.com

About Family Features Editorial Syndicate

A leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at Culinary.net and eLivingToday.com.

SOURCE: Family Features

ReleaseID: 618382

LOS ANGELES, CA / ACCESSWIRE / November 25, 2020 / Kevin Lenaghan is excited to announce the launch of a new business venture, Ivy Academy LLC ("the company"). Based in Los Angeles, California, the company provides investment advisory services for sophisticated global investors, as well as admissions counseling services.

Ivy Academy LLC's investment advisory division provide bespoke advisory services for high net worth, family offices, and endowments & foundations, that are customized for the client's individual circumstances. The company helps clients construct and manage alternative asset portfolios, with an emphasis on sustainable alpha strategies, dislocated asset classes, co-investments and partnership approaches. Ivy Academy LLC also provides support with both strategic and tactical asset allocation. Clients benefit from the founder's deep and diverse exposure to hedge funds and other alternative asset classes across many different strategies, geographies, and firm types. Where appropriate, Ivy Academy LLC partners with other external advisors on topics like tax efficiency, estate planning, and charitable giving.

On the admissions counseling side, the company works with accomplished and ambitious students who are applying to top-tier undergraduate and graduate programs. We provide high-touch, multidisciplinary consulting services to guide our clients through all aspects of the admissions process. Ivy Academy LLC has established a global presence, with an emphasis on Chinese students seeking admission to US universities. Importantly, Ivy Academy LLC emphasizes excellence and integrity at all times, while pushing our students to improve themselves, explore their passions, and target optimal schools.

Kevin Lenaghan has more than 20 years of experience in financial services and investment management. He attended the Wharton School of the University of Pennsylvania, where he completed his undergraduate studies as well as his MBA. Kevin is a CFA charterholder and serves as an advisor and pro bono teaching fellow for Musical Mentors Collaborative (http://musical-mentors.org).

"I am proud to leverage my prior investment experience, extensive professional network, and current insights to provide innovative investment solutions for our partners. Global markets are endlessly fascinating and evolving, and I will continue diligently working to identify differentiated alpha opportunities in order to deliver value for clients." says Kevin Lenaghan.

For more information, please visit http://ivyacademyllc.com/.

About Kevin Lenaghan

Kevin Lenaghan has more than 20 years of experience in financial services and investment management, including over 12 years of experience in direct hedge fund investing. He obtained both his undergraduate degree and MBA from the Wharton School of the University of Pennsylvania and is a CFA charterholder. Throughout his career, Kevin has worked with many of the largest and most sophisticated institutional investors on their hedge fund and broader alternatives portfolios, as well as asset allocation. He has regularly spoken at prestigious hedge fund and investment conferences and has been widely cited in leading industry publications. Currently, Mr. Lenaghan is the CEO of Ivy Academy LLC. He lives in Los Angeles, California, with his wife Linda and two children, Benjamin and Emma.

For more information, visit https://kevin-lenaghan.com/.

Contact Information:

Kevin Lenaghan
Email: kevin@ivyacademyllc.com

SOURCE: Kevin Lenaghan

ReleaseID: 618372

MONTEVIDEO, URUGUAY / ACCESSWIRE / November 25, 2020 / Money On Chain is pleased to announce the launch of TEX, a new decentralized token exchange built on RSK, Bitcoin's smart contract sidechain. TEX automates token swaps using smart contracts, offering users access to DoC, BPro, RIF, and rBTC, among others. The launch further expands the footprint of Bitcoin DeFi based on the RSK technology stack.

The TEX uses a unique trading mechanism, inspired by the method used at The London Gold Fix, which sets the value of gold twice a day. Based on an Order Book (OB), the order execution is not instantaneous and occurs on ticks. Ticks occur every few minutes to allow the order book to form a price to be discovered before the match is made. The frequency of ticks depends on market activity. This is especially important in a new network and enables organic liquidity growth. Users who place orders in the OB can cancel them at any time.

With the public order book, the TEX design avoids front-running, and with pricing via ticks, TEX aims to ensure a fairer price discovery, even at low trading volume.

Max Carjuzaa, co-founder of Money On Chain commented: "The TEX is an important piece of the Money On Chain protocol. The decentralized order book ensures a fair and transparent price discovery process and establishes a secondary market for tokens."

The TEX has two types of orders: Limit Orders and Market Maker Orders.

A limit order lets the trader set the trade conditions to ensure that they buy or sell at the intended price or better. The buyer will not spend more than the maximum they were willing to pay, and the seller will not receive less than the minimum they were expecting to obtain. The price will be the average between the two.

A market maker order is a special type of limit order. Here, the trader specifies a percentage difference with a fair price. The TEX obtains fair pricing from an oracle or the last tick where an oracle is not available.

TEX is designed to be a fairer way to trade in a Bitcoin ecosystem. TEX is already live, so traders can immediately start trading in a decentralized and transparent manner.

Diego Gutierrez Zaldivar, CEO of IOVlabs added: "We are very excited about this announcement that shows momentum for Bitcoin Defi is growing. Decentralized exchanges, together with sovereign digital identities will play a key role in Bitcoin's future and provide the core tools for financial freedom."

For more information about the TEX visit: https://moneyonchain.com/tex-bitcoin-decentralized-exchange/

About Money on Chain

Money On Chain wants to bring Bitcoin to mass adoption. To that end, it offers solutions to meet the needs of different types of users: a fully bitcoin-collateralized stablecoin (DoC), a bitcoin on steroids (BPro) and a dizzying bitcoiner option for lovers of leveraged trading (BTCx). All this, without requiring the delivery of private keys. To make this possible, it developed an unique mathematical-financial model with proven robustness, even in extreme market situations.

For more information, visit https://moneyonchain.com/

About RSK

The RSK network is the most secure smart contract platform in the world, secured by Bitcoin's unparalleled hash power via merge-mining.

RSK adds value and functionality to the bitcoin ecosystem by enabling smart-contracts, near instant payments, and higher-scalability.

The network scales to up to 100 transactions per second without sacrificing decentralization, and reduces storage and bandwidth using probabilistic verification, fraud detection, and more.

For more information visit https://www.rsk.co/rsk-blockchain/

Contact

Dan Edelstein
pr@marketacross.com
+972-545-464-238

SOURCE: IOV Labs

ReleaseID: 618339

MIAMI, FL / ACCESSWIRE / November 25, 2020 / The holidays are upon us, and with the traditional "shopping season" in full swing, eCommerce businesses are scrambling to button up last-minute deals and strategies to make this season a great one (despite the economic downturn).

According to the National Retail Federation (NRF), holiday shopping between November and December has traditionally represented 19% or more of the entire year's sales for many businesses. In light of COVID and a consumer shift from in-store to online shopping, this year is projected by some to be a challenging one for many eCommerce businesses caught off guard by the influx of online shoppers.

Research published on CNBC and others suggests that up to 44% of consumers plan on spending less this holiday season. According to Next Level Marketing, this makes partnering with a reputable marketing company that much more important for the 2020 holiday season.

Next Level Marketing Taps Into the Holiday Shopping Craze

The holiday season is, first and foremost, about family and being thankful. But beyond that, it is a time when shoppers splurge at the checkout. Next Level Marketing brings decades of experience to the table, having helped hundreds of clients, from budding startups to multinational corporations navigate the holiday season rush with stride.

For those looking to capitalize on the seasonal shopping bonanza, few channels produce as good of results as eCommerce SEM and eCommerce SEO. When used together, these two digital marketing strategies pack a 1-2 knockout punch, delivering scalable and reliable results with paid ads, while leveraging the power of organic (free) traffic that lasts well beyond the holiday rush.

eCommerce SEO and SEM

eCommerce SEO

eCommerce platforms pose unique challenges when it comes to search engine optimization. Complex code, hundreds or even thousands of SKUs, coupons, code structure, CMS limitations, and more all add to the difficulty of getting it done right.

Due to the complexity, and potential to do more harm than good, Next Level Marketing stresses the importance of partnering with a digital marketing agency that has a deep working knowledge of eCommerce platforms, and that knows how to best leverage its strengths while mitigating any weaknesses in order to get the most out of any strategies employed.

eCommerce SEM

Google search is a critical element in the buying cycle for virtually all goods and services, with more than 83% of all sales cycles having search as a key touchpoint in the buying decision process. Properly optimizing this channel before the peak season can set up a business for long-term success well beyond the holiday shopping months.

Elements of eCommerce SEO Include:

Keyword optimization
Site architecture structuring and restructuring
Product descriptions and headlines optimization
On-page SEO and local SEO optimization
Link-building strategies
Enhancing the user experience
Optimizing for conversion rates
Implementing dynamic tracking to measure site performance
And more…

Elements of eCommerce SEM Include:

Ad design and testing
Audience targeting
Audience segmentation
Retargeting campaigns
Cart abandonment campaigns
Budget optimization
And more…

What Businesses Can Do Right Now to Prepare

Next Level Marketing warns to avoid waiting until the last minute. There is no time like yesterday to begin planning and executing a strategy.

Ideas to Get Started on, and what to avoid:

Holiday deals
Holiday-specific product categories and landers
Repositioning content
Adding structured data
Increase customer service hours
Speak with hosting providers about elastic increases in resources
Shore up any errors or issues that may impact performance
And more…

About Next Level Marketing

Next Level Marketing is one of the nation's leading marketing firms, backed by an impressive resume of results for clients large and small. Having worked with businesses ranging from local mom and pop operations, to multinational Fortune 500 companies, Next Level Marketing is capable and ready to tackle any challenge this holiday season.

Those interested in learning more about NLM or in partnering with an award-winning digital marketing agency this season, are encouraged to reach out via their official website.

CONTACT:

Company Name: Next Level Marketing
Contact Person: Tomas Gallo
Email: tomas@nextlevelsem.com
Phone: (844) 740-5010
Address: 2125 Biscayne Blvd, Miami FL 33137
Website: www.nextlevelsem.com

SOURCE: Next Level Marketing

ReleaseID: 618356

PHOENIX, AZ / ACCESSWIRE / November 25, 2020 / Alpine 4 Technologies, Ltd., (OTCQB:ALPP) owner of leading small market businesses, officially welcomes Larry Zic as its VP / Corporate Controller.

Mr. Zic brings a wealth of knowledge and experience to the Alpine 4 leadership team. He received a double Bachelors in both Accounting and Computer Information Systems from St. Joseph College and his MBA from Indiana University. Larry received his CPA and began his public accounting career at a regional Chicago based accounting firm. In addition to being a CFO of an international retail business, Mr. Zic was a Senior Vice President of Finance for Saks, Inc., a $5b annual retail department store chain. He has been part of implementing 12 ERP systems over his career. It is this experience that will help advance the execution of Alpine 4's SPECTRUMebos ERP system both internally and commercially. Additionally, Mr. Zic taught auditing at Purdue University. He will assist in keeping the Alpine 4 leadership team up to date and compliant with accounting and auditing policy and procedures. The expertise of Larry and his team has already proven to be integral in our auditors' work being released on time.

Kent Wilson, CEO of Alpine 4 commented, "Larry is the right guy at the right time and we are ecstatic to have him on board with us. It was long overdue for the company to fill this position and the results since Larry's arrival have been stellar. Larry has brought a maturity and assemblance of proper procedure, that will eventually reduce our overall auditing cost and material output to produce our company's financial statements."

Mr. Zic had this to say, "I am very pleased to be part of the Alpine 4 team. I am fortunate to have a diverse career where Kent affords me the ability to apply my experiences in various ways within the company. His vision for the company is quite contagious and gives me comfort in our ability to execute. "Alpine 4: Four principles at the core of our business are Synergy. Innovation. Drive. Excellence. At Alpine 4, we believe synergistic innovation drives excellence. By anchoring these words to our combined experience and capabilities, we can aggressively pursue opportunities within and across vertical markets. We deliver solutions that not only drive industry standards but also increase value for our shareholders.

Contact: Kent B. Wilson, CEO or Ian Kantrowitz, VP of Investor Relations
investorrelations@alpine4.com
www.alpine4.com

Forward-Looking Statements: The information disclosed in this press release is made as of the date hereof and reflects Alpine 4 most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Alpine 4 believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Alpine 4 disclaims any intention or obligation to update the forward-looking statements for subsequent events.

SOURCE: Alpine 4 Technologies, Ltd.

ReleaseID: 618357

CHARLOTTESVILLE, VA / ACCESSWIRE / November 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has entered into a Common Stock Purchase Agreement (the "Purchase Agreement") with Keystone Capital Partners ("Keystone Capital"), a New York-based family office with investments in biotech, real estate and consumer products. Pursuant to the Purchase Agreement, the Company will have the right to sell to Keystone Capital up to $15 million of the Company's common stock from time-to-time during the term of the Purchase Agreement subject to certain conditions including the effectiveness of a registration statement relating to the shares. Sales of common stock, and the timing of any sales, are solely at the option of the Company and the Company is under no obligation to sell securities pursuant to this arrangement.

"We decided to enter into this agreement with Keystone as we believe they have a strong fundamental understanding our business, and are an ideal strategic partner to support any financial needs that may arise," said William Stilley, CEO of Adial Pharmaceuticals. "We have no immediate plans to raise capital, with over $7 million of cash on hand as of September 30, 2020; however, this transaction provides additional flexibility and capability to take advantage of strategic opportunities and future growth initiatives when they may arise."

"We are pleased to enter into this relationship with Adial," said Fred Zaino, Managing Partner and Chief Investment Officer of Keystone. "After evaluating Adial, its clinical pipeline, and its management team, and after thorough due diligence, we believe Adial represents a promising investment opportunity. Formation of this partnership memorializes our intention to build a long-term relationship with Adial, committing capital as necessary as the Company builds its business in the growing space of addiction that is currently woefully underserved."

Details of the Purchase Agreement and Registration Rights Agreement are available in the Company's Form 8-K, which has been filed with the securities and Exchange Commission and is available at www.sec.gov or visit the Company's web site here.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in a Phase 3 clinical for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.

www.adialpharma.com

About Keystone Capital Partners

Founded in 2019, Keystone Capital Partners is a family office based in New York with investments in biotech, real estate and consumer products.

To learn more about the Keystone team, visit www.keystone-cp.com

Forward Looking Statements

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to, our ability to enroll patients and complete clinical trials on time and achieve desired results and benefits as expected, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Adial Pharmaceuticals Investor Relations:
Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: adil@crescendo-ir.com

Keystone Media Relations:
ICR
Nicole Hakimi
Phone: +1-646-677-1802
Email: KeystoneCP@icrinc.com

SOURCE: Adial Pharmaceutical, Inc.

ReleaseID: 618354

NEW YORK, NY and LOS ANGELES, CA / ACCESSWIRE / November 25, 2020 / Dolphin Entertainment, Inc. (NASDAQ:DLPN), a leading independent entertainment marketing and premium content production company, today announced that the company will effect a 1-for-5 reverse split of its issued and outstanding shares of common stock. The reverse stock split will become effective November 27, 2020 at 12:01 a.m. EDT. Shares of the company's common stock will trade on a split-adjusted basis on The NASDAQ Capital Market, as of the opening of trading on Friday, November 27, 2020. The new CUSIP number for the Company's common stock will be 25686H 209.

The reverse stock split is being affected as part of the company's plan to regain compliance with the $1.00 minimum bid price continued listing requirement of The NASDAQ Capital Market.

When the reverse stock split becomes effective, every five shares of Dolphin Entertainment's common stock will be automatically combined into one new share of common stock. No fractional shares will be issued, and no cash or other consideration will be paid. Instead, the company will issue one whole share of the post-split common stock to any stockholder of record who otherwise would have received a fractional share as a result of the reverse stock split.

The reverse stock split will reduce the number of shares of outstanding common stock from approximately 32.8 million shares to approximately 6.6 million shares.

Dolphin Entertainment's transfer agent is Nevada Agency and Transfer Company. Stockholders holding paper certificates representing pre-split holdings can contact our transfer agent by calling 775-322-0626 for the procedure to exchange existing stock certificates for new stock certificates or book-entry shares. Certificates representing pre-split holdings will be deemed to represent the stockholder's past split holdings until the stockholder presents the certificate to the transfer agent. Stockholders who are holding their shares in electronic form at their brokerage firms do not have to take any action as the effects of the reverse stock split will automatically be reflected in their brokerage accounts.

About Dolphin Entertainment, Inc.
Dolphin Entertainment is a leading independent entertainment marketing and premium content development company. Through our subsidiaries 42West, The Door and Shore Fire Media, we provide expert strategic marketing and publicity services to many of the top brands, both individual and corporate, in the film, television, music and hospitality industries. Viewpoint Creative and Be Social complement their efforts with full-service creative branding and production capabilities as well as social media and influencer marketing services. Dolphin's legacy content production business, founded by Emmy-nominated CEO Bill O'Dowd, has produced multiple feature films and award-winning digital series.

This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements may address, among other things, Dolphin Entertainment Inc.'s offering of common stock as well as expected financial and operational results and the related assumptions underlying its expected results. These forward-looking statements are distinguished by the use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, Dolphin Entertainment's actual results may differ materially from the results discussed in its forward-looking statements. Dolphin Entertainment's forward-looking statements contained herein speak only as of the date of this press release. Factors or events Dolphin Entertainment cannot predict, including those described in the risk factors contained in its filings with the Securities and Exchange Commission, may cause its actual results to differ from those expressed in forward-looking statements. Although Dolphin Entertainment believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be achieved, and Dolphin Entertainment undertakes no obligation to update publicly any forward-looking statements as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACT:
James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

SOURCE: Dolphin Entertainment

ReleaseID: 618355

Fishing Reels market players are enhancing their profitability and proficiency by manufacturing as well as developing innovative products across diverse fishing reel segments.

ROCKVILLE, MD / ACCESSWIRE / November 25, 2020 / The global fishing reels market will be exhibiting a sturdy CAGR of 4% throughout the forecast period of 2020-2030. Growing demand from recreational anglers and the growing popularity of sports fishing is poised to extend the market growth in the approaching years.

"Growing popularity of sports fishing in emerging nation of South Asia is slated to open up several prospects for the fishing reels market." says the Fact.MR report.

Fishing Reels Market- Key Takeaways

Currently, North America holds the highest market share, trailed by Europe.
Freshwater fishing type is anticipated to unlock more growth prospects throughout the forecast period
Anti-reversal fishing reels mechanism will record a CAGR of 4.5% during the forecast period.
E-Commerce websites sales channel to gain traction due to the COVID-19 pandemic.
Spinning reels type category are likely to record a CAGR of 4% during 2020-2030

Request a report sample to gain comprehensive market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=1543

Fishing Reels Market – Driving Factors

Growing popularity of sports fishing is anticipated to fuel demand for fishing accessories over the assessment period.
Accomplishing ease of handling in the devices with the assistance of recent progressions in their designing processes are boosting the fishing equipment market
Collaboration with sports fishing companies for innovation, product customization, and attaining USP regarding the product to boost demand.

Fishing Reels Market – Constraints

Fluctuating prices of raw materials are anticipated to constrain the market growth
Probability of corrosion in the internal components of fishing reels to hamper sales in the global market.

Anticipated Market Impact by COVID-19 Outbreak

The COVID-19 outbreak has restricted the expansion of the fishing reels market. North America, one of the leading regions in the fishing reels market, is anticipated to see an extreme decline in demand since it has been the most impacted region by the pandemic. On the other hand, amid the slump for offline sales of fishing reels, increasing usage of virtual technologies is projected to improve online shopping amid consumers, and will gradually boost sales in the post-COVID era.

Explore the global Fishing Reels market with 147 figures, 80 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/1543/fishing-reels-market

Competition Landscape

Major companies in the Fishing Reels market are Shimano Inc., Bass Pro Shops, Pure Fishing, Inc, Clam Outdoors, Rapala VMC Corporation, Zebco, NingBo HaiBao Fishing Tackle Co., Ltd., Jiu Yu Fishing Tackle Co., Ltd., Weihai Guangwei Group Co., Ltd., and Okuma Fishing Tackle Co., Ltd.

More on the Report

The Fact.MR's market research report provides in-depth insights into the Fishing Reels market. The market is scrutinized based on type (spinning reels, spincast reels, baitcaster reels, trolling reels, offshore reels, and others), reel mechanism (anti-reverse reels and direct-drive reels), fishing type (freshwater fishing, saltwater fishing, and great lake fishing), and sales channel (outdoor sports stores, modern trade channels, other channels, and online retail [company websites and third-party online]), across five major regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA)).

Explore Wide-ranging Coverage of Fact.MR's Sports Landscape

Fishing Hooks Market: Find insights on the fishing hooks market with analysis of segments, statistics, influencers, market players, and business strategies adopted over a 10-year forecast period.

Fishing Rods Market: Read an analysis of the fishing rods market with insights on growth factors, opportunities, restraints, regional market forecast, regulatory policies, and strengths of market leaders.

Fishing Tackle Box Market: Fact.MR's report on the Fishing Tackle Box market offers insights on the market during 2018-2028, including restraints, revenue sources, market leaders, and market strategies.

About Fact.MR

Fact.MR is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Fact.MR is headquartered in Dublin, and has offices in Dubai. Fact.MR's latest market research reports industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1716/global-fishing-reels-market

SOURCE: FactMR

ReleaseID: 618351